Quarterly ResultMay 7, 2026, 08:13 AM
Edgewise Therapeutics Q1 Net Loss $(49.0)M; R&D up 16%
AI Summary
Edgewise Therapeutics reported a net loss of $(49.0) million for the first quarter of 2026, an increase from $(40.8) million in the prior year, primarily due to higher operating expenses. Research and development expenses rose by 16% to $42.7 million as the company continued to advance its late-stage clinical programs for severe muscle diseases. As of March 31, 2026, the company held $499.6 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next 12 months.
Key Highlights
- Net loss for Q1 2026 was $(49.0) million, up from $(40.8) million in Q1 2025.
- Net loss per share was $(0.46) in Q1 2026, compared to $(0.43) in Q1 2025.
- Total operating expenses increased by 17.7% to $54.1 million in Q1 2026.
- Research and development expenses rose 16.0% to $42.7 million in Q1 2026.
- Cash, cash equivalents, and marketable securities totaled $499.6 million as of March 31, 2026.
- Company expects current capital to fund operations for at least the next 12 months.
- Lead product candidates sevasemten and EDG-7500 are in Phase 2 clinical trials.